carubicin and Remission--Spontaneous

The therapeutic effect of carminomycin was studied in clinic at different treatment schemes with respect to 14 children and juvenile patients with osteogenic sarcoma. Pronounced local effect evident from disappearance of the pain and in some cases decrease of the metastatic tumor were noted in the patients with metastases of the osteogenic sarcoma to the bones or relapses of the primary tumor. Subjective improvement and objective effect were observed respectively in 90 and 53 per cent of the patients with metastases into the lungs and pronounced lung symptomatology.

Topics: Adolescent; Antibiotics, Antineoplastic; Arm; Bone Neoplasms; Carubicin; Child; Child, Preschool; Clinical Trials as Topic; Drug Evaluation; Humans; Leg; Neoplasm Metastasis; Osteosarcoma; Remission, Spontaneous; Time Factors

Side reactions and therapeutic effect of carminomycin were studied in 21 children with various malignant tumors. Carminomycin was administered intravenously in doses of 0.15-0.2 mg/kg twice a week for 2-3 weeks. The treatment courses were repeated in a month. The drug was better tolerated by children than by adults. After the treatment course leucopenia may develop. When used alone or in combination with vincristin or cyclophosphan carminomycin proved to be effective in treatment of sarcoma of the soft tissues (liposarcoma, synovial sarcoma), chondrosarcoma and reticulosarcoma.

Topics: Adolescent; Antibiotics, Antineoplastic; Carubicin; Child; Child, Preschool; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Moscow; Neoplasms; Remission, Spontaneous; Sarcoma

A total of 39 patients with sarcoma of the soft tissues were treated with carminomycin administered intravenously in doses of 10-15 mg twice a week, the total dose being 60-70 mg. The intervals between the courses were 1 month. The objective effect was observed in 17 out of 39 patients, i. e. 43.6%. The tumor decrease was registered in 6 out of 15 patients with leuomyosarcoma, in 3 out of 6 patients with synovial sarcoma, in 2 out of 4 patients with robdomyosarcoma, in 1 out of 4 patients with angiosarcoma, in 1 out of 3 patients with fibrosarcoma, in 1 patient with liposarcoma and in 3 out of 5 patients with stromal sarcoma of the uterus. A necessity for repeated treatment courses in spite of a positive effect or absence of the disease progress is underlined.

Topics: Aged; Antibiotics, Antineoplastic; Carubicin; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Moscow; Neoplasm Metastasis; Remission, Spontaneous; Sarcoma; Soft Tissue Neoplasms

The clinical trials of karminomycin, a new Soviet antitumor antibiotic in treatment of different malignant tumors showed that the drug had a pronounced antitumor activity against the soft tissue sarcomas of various histogenesis, lympho- and reticulosarcoma, acute leukemia and some other neoplasms.

Topics: Adolescent; Antibiotics, Antineoplastic; Carubicin; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Male; Middle Aged; Neoplasms; Remission, Spontaneous; USSR

Topics: Animals; Antibiotics, Antineoplastic; Carubicin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Leukemia L1210; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Remission, Spontaneous; Time Factors